Lundbeck presents positive Phase IIb data for bocunebart (Lu AG09222; anti-PACAP mAb) in migraine prevention at the AHS congress ...Middle East

The intravenous part of the Phase IIb clinical dose-finding trial PROCEED met its primary endpoint, with bocunebart demonstrating a statistically significant reduction in monthly migraine days versus placebo over Weeks 1–12 in patients with one to four prior preventive treatment failures...

Hence then, the article about lundbeck presents positive phase iib data for bocunebart lu ag09222 anti pacap mab in migraine prevention at the ahs congress was published today ( Friday 05/06/2026 - 12:06 AM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Lundbeck presents positive Phase IIb data for bocunebart (Lu AG09222; anti-PACAP mAb) in migraine prevention at the AHS congress )

Also on site :

• Hundreds of Stanford students walked out of their grad ceremony to protest Google CEO’s commencement speech. It wasn’t all about AI
• Dodgers To Activate Tommy Edman On Tuesday
• Cape Verde Goalkeeper Gains Over 2 Million Instagram Followers After Heroic World Cup  Performance in Draw Against Spain